Denmark Outlines Vision For Decentralized Trials Beyond COVID-19
Executive Summary
The Danish medicines regulator has set out its expectations on key elements of decentralized clinical trials as part of Denmark’s ongoing effort to develop a robust regulatory framework in this area.
You may also be interested in...
Are Trial Sponsors Treading On Investigators’ Toes In Decentralized Trials?
The Danish regulator’s experience with reviewing and inspecting decentralized elements in clinical trials highlights concerns around the blurring of lines that divide the roles and responsibilities of sponsors and trial investigators.
Embracing Decentralized Trials Is Not ‘Plug And Play’
Trial sponsors are proactively seeking opportunities to incorporate decentralized elements into their studies, but the lack of regulatory guidance makes it a difficult exercise.
Sweden Tackles Regulatory Barriers To Decentralized Trials
The COVID-19 pandemic has given a new impetus to Sweden’s ongoing efforts to support decentralized clinical trials.